Point of Care Manufacturing
We are Opening the World
to Cell and Gene Therapies
Millions of CGT patients worldwide may not have access to potentially transformative therapies. Until now.
Transforming the Process
We rebuilt the complete service and logistics model to bring the promise of CGT clinical trials to logistically disconnected patients worldwide. This breakthrough now provides a single turn-key solution for the study sponsor. This can enable faster enrollment, and may speed the path to commercialization.
End to end operations
From screening to post-infusion follow-up visits, Boston Labs provides an in-country solution to current logistical barriers.
Our global operations centers will provide the analytical testing, clinical and operational support for our decentralized manufacturing network. All technical services remain local. This expands the available patient population.
AFRICA . SOUTH AMERICA . MENA . INDIA
In December 2021 Boston Labs collaborated with Germfree Laboratories to demonstrate the feasibility of growing human cells and maintaining sterility over a 10 day period in a mobile clean room manufacturing environment. We succeeded. Positioned in a parking lot in Florida, the Germfree mobile cleanroom performed brilliantly. Our procedures, equipment and technical expertise came together to prove that open process sterility can be maintained in a decentralized platform. We will soon be announcing a CAR-T closed process study for Q1 2023.
Our new Boston cGMP manufacturing facility will be online Q1 2023
Let's start the conversation
Learn about our global strategy to bring your CGT therapy to patients worldwide.